Chu Yu-Waye
SEC CIK 1854586 · EDGAR
BoughtSold
Most active insiders at CTMX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | McCarthy Sean A. | CEO, Dir | — | $1.23M |
| 2 | BELVIN MARCIA | SVP, CSO | — | $202.2K |
| 3 | Chu Yu-Waye | Chief Medical Off | — | $136.6K |
| 4 | Ogden Christopher | CFO | — | $129.0K |
| 5 | Lester Rachael | Chief Business Off | — | — |
| 6 | Carvajal Alejandra | CLO | — | — |
Transactions 13
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-19 | 2026-03-17 | CTMX | CytomX Therapeutics, Inc. | Chu Yu-Waye | Chief Medical Off | S - Sale | $6.42 | -21.3K | 189.4K | -10% | -$136.6K | |
| D | 2026-02-04 | 2026-02-02 | CTMX | CytomX Therapeutics, Inc. | Chu Yu-Waye | Chief Medical Off | A - Grant | $0.00 | +75.0K | 210.7K | +55% | $0 |
| 2025-03-20 | 2025-03-18 | CTMX | CytomX Therapeutics, Inc. | Chu Yu-Waye | Chief Medical Off | S - Sale | $0.6 | -4,025 | 135.7K | -3% | -$2,415 | |
| DM | 2025-02-06 | 2025-02-04 | CTMX | CytomX Therapeutics, Inc. | Chu Yu-Waye | Chief Medical Off | A - Grant | $0.00 | +113.5K | 82.2K | New | $0 |
| D | 2024-01-19 | 2024-01-18 | CTMX | CytomX Therapeutics, Inc. | Chu Yu-Waye | Chief Medical Off | A - Grant | $0.00 | +26.2K | 26.2K | New | $0 |
| M | 2023-04-19 | 2023-04-18 | FATE | FATE THERAPEUTICS INC | Chu Yu-Waye | Chief Medical Off | S - Sale | $6.57 | -2,532 | 140.7K | -2% | -$16.6K |
| 2023-01-11 | 2023-01-10 | FATE | FATE THERAPEUTICS INC | Chu Yu-Waye | Chief Medical Off | S - Sale | $5.24 | -7,825 | 143.2K | -5% | -$41.0K | |
| 2022-04-21 | 2022-04-19 | FATE | FATE THERAPEUTICS INC | Chu Yu-Waye | Chief Medical Off | S - Sale | $35.37 | -4,062 | 151.0K | -3% | -$143.7K | |
| D | 2022-01-27 | 2022-01-25 | FATE | FATE THERAPEUTICS INC | Chu Yu-Waye | Chief Medical Off | A - Grant | $0.00 | +33.3K | 155.1K | +27% | $0 |
| M | 2022-01-13 | 2022-01-11 | FATE | FATE THERAPEUTICS INC | Chu Yu-Waye | Senior VP Clinical Development | S - Sale | $48.51 | -3,965 | 121.8K | -3% | -$192.3K |
| DM | 2021-12-13 | 2021-12-10 | FATE | FATE THERAPEUTICS INC | Chu Yu-Waye | Senior VP Clinical Development | S - Sale+OE | $51.46 | -7,500 | 130.3K | -5% | -$385.9K |
| D | 2021-12-13 | 2021-12-10 | FATE | FATE THERAPEUTICS INC | Chu Yu-Waye | Senior VP Clinical Development | M - OptEx | $16.32 | +7,500 | 133.3K | +6% | +$122.4K |
| 2021-11-22 | 2021-11-19 | FATE | FATE THERAPEUTICS INC | Chu Yu-Waye | Senior VP Clinical Development | A - Grant | $0.00 | +61.0K | 125.8K | +94% | $0 |
Purchase Sale Sale after option exercise All abbreviations